Difference between revisions of "Oprelvekin (Neumega)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. | Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. | ||
| − | =History of changes in FDA indication= | + | ==History of changes in FDA indication== |
| − | *11 | + | *1997-11-25: Initial FDA approval (no label available on Drugs @ FDA) |
| − | * | + | *2002-09-18: Label indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. |
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Neumega | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Subcutaneous medications]] | ||
| + | |||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
Latest revision as of 13:58, 8 June 2023
Mechanism of action
Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
History of changes in FDA indication
- 1997-11-25: Initial FDA approval (no label available on Drugs @ FDA)
- 2002-09-18: Label indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.
Also known as
- Brand name: Neumega